{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:49:48Z","timestamp":1793713788182,"version":"4.6.1"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41401-020-00565-5","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T06:08:04Z","timestamp":1606889284000},"page":"1382-1389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["New therapeutics beyond amyloid-\u03b2 and tau for the treatment of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"42","author":[{"given":"Feng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-jia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-dong","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"565_CR1","unstructured":"World Health Organization. Dementia fact sheets. 2019. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"565_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-med-042915-103753","volume":"68","author":"WV Graham","year":"2017","unstructured":"Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer\u2019s disease therapy and prevention strategies. Annu Rev Med. 2017;68:413\u201330.","journal-title":"Annu Rev Med"},{"key":"565_CR3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553\u201362.","journal-title":"Neurology"},{"key":"565_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"565_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378:321\u201330.","journal-title":"N Engl J Med"},{"key":"565_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","volume":"15","author":"DJ Selkoe","year":"2019","unstructured":"Selkoe DJ. Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol. 2019;15:365\u20136.","journal-title":"Nat Rev Neurol"},{"key":"565_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9:95.","journal-title":"Alzheimers Res Ther"},{"key":"565_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. Randomized trial of Verubecestat for prodromal Alzheimer\u2019s disease. N Engl J Med. 2019;380:1408\u201320.","journal-title":"N Engl J Med"},{"key":"565_CR9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMc1813435","volume":"380","author":"D Henley","year":"2019","unstructured":"Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. Preliminary results of a trial of Atabecestat in preclinical Alzheimer\u2019s disease. N Engl J Med. 2019;380:1483\u20135.","journal-title":"N Engl J Med"},{"key":"565_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","volume":"77","author":"AM Wessels","year":"2019","unstructured":"Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, et al. Efficacy and safety of Lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials. JAMA Neurol. 2019;77:199\u2013209.","journal-title":"JAMA Neurol"},{"key":"565_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00401-017-1804-9","volume":"135","author":"F Peters","year":"2018","unstructured":"Peters F, Salihoglu H, Rodrigues E, Herzog E, Blume T, Filser S, et al. BACE1 inhibition more effectively suppresses initiation than progression of beta-amyloid pathology. Acta Neuropathol. 2018;135:695\u2013710.","journal-title":"Acta Neuropathol"},{"key":"565_CR12","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","volume":"31","author":"C Wiessner","year":"2011","unstructured":"Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011;31:9323\u201331.","journal-title":"J Neurosci"},{"key":"565_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ana.25513","volume":"86","author":"T Yang","year":"2019","unstructured":"Yang T, Dang Y, Ostaszewski B, Mengel D, Steffen V, Rabe C, et al. Target engagement in an alzheimer trial: Crenezumab lowers amyloid beta oligomers in cerebrospinal fluid. Ann Neurol. 2019;86:215\u201324.","journal-title":"Ann Neurol"},{"key":"565_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13195-018-0436-1","volume":"10","author":"P Novak","year":"2018","unstructured":"Novak P, Schmidt R, Kontsekova E, Kovacech B, Smolek T, Katina S, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10:108.","journal-title":"Alzheimers Res Ther"},{"key":"565_CR15","first-page":"236","volume":"4","author":"T West","year":"2017","unstructured":"West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer\u2019s disease and other tauopathies. J Prev Alzheimers Dis. 2017;4:236\u201341.","journal-title":"J Prev Alzheimers Dis"},{"key":"565_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","volume":"18","author":"AL Boxer","year":"2019","unstructured":"Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019;18:549\u201358.","journal-title":"Lancet Neurol"},{"key":"565_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-014-1375-y","volume":"129","author":"DR Thal","year":"2015","unstructured":"Thal DR, Walter J, Saido TC, Fandrich M. Neuropathology and biochemistry of Abeta and its aggregates in Alzheimer\u2019s disease. Acta Neuropathol. 2015;129:167\u201382.","journal-title":"Acta Neuropathol"},{"key":"565_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrneurol.2013.223","volume":"9","author":"E Giacobini","year":"2013","unstructured":"Giacobini E, Gold G. Alzheimer disease therapy-moving from amyloid-beta to tau. Nat Rev Neurol. 2013;9:677\u201386.","journal-title":"Nat Rev Neurol"},{"key":"565_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P. Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement. 2016;12:719\u201332.","journal-title":"Alzheimers Dement"},{"key":"565_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fnagi.2017.00282","volume":"9","author":"F Zhang","year":"2017","unstructured":"Zhang F, Zhong R, Li S, Fu Z, Cheng C, Cai H, et al. Acute hypoxia induced an imbalanced M1\/M2 activation of microglia through NF-kappaB signaling in Alzheimer\u2019s disease mice and wild-type littermates. Front Aging Neurosci. 2017;9:282.","journal-title":"Front Aging Neurosci"},{"key":"565_CR21","first-page":"316523","volume":"2013","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer\u2019s disease. Oxid Med Cell Longev. 2013;2013:316523.","journal-title":"Oxid Med Cell Longev"},{"key":"565_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.14336\/AD.2015.1007","volume":"7","author":"IG Onyango","year":"2016","unstructured":"Onyango IG, Dennis J, Khan SM. Mitochondrial dysfunction in Alzheimer\u2019s disease and the rationale for bioenergetics based therapies. Aging Dis. 2016;7:201\u201314.","journal-title":"Aging Dis"},{"key":"565_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fnins.2018.00314","volume":"12","author":"F Zhang","year":"2018","unstructured":"Zhang F, Zhong R, Qi H, Li S, Cheng C, Liu X, et al. Impacts of acute hypoxia on Alzheimer\u2019s disease-like pathologies in APP(swe)\/PS1(dE9) mice and their wild type littermates. Front Neurosci. 2018;12:314.","journal-title":"Front Neurosci"},{"key":"565_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/bies.201400002","volume":"36","author":"P Nilsson","year":"2014","unstructured":"Nilsson P, Saido TC. Dual roles for autophagy: degradation and secretion of Alzheimer\u2019s disease Abeta peptide. Bioessays. 2014;36:570\u20138.","journal-title":"Bioessays"},{"key":"565_CR25","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141:1917\u201333.","journal-title":"Brain"},{"key":"565_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-019-1049-5","volume":"21","author":"LJ Bessey","year":"2019","unstructured":"Bessey LJ, Walaszek A. Management of behavioral and psychological symptoms of dementia. Curr Psychiatry Rep. 2019;21:66.","journal-title":"Curr Psychiatry Rep"},{"key":"565_CR27","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3389\/fphar.2020.01168","volume":"11","author":"R Magierski","year":"2020","unstructured":"Magierski R, Sobow T, Schwertner E, Religa D. Pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress. Front Pharmacol. 2020;11:1168.","journal-title":"Front Pharmacol"},{"key":"565_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00702-017-1696-9","volume":"124","author":"F Zhang","year":"2017","unstructured":"Zhang F, Zhong R, Li S, Chang RC, Le W. The missing link between sleep disorders and age-related dementia: recent evidence and plausible mechanisms. J Neural Transm. 2017;124:559\u201368.","journal-title":"J Neural Transm"},{"key":"565_CR29","doi-asserted-by":"publisher","first-page":"112140","DOI":"10.1016\/j.ejmech.2020.112140","volume":"191","author":"S Mozaffarnia","year":"2020","unstructured":"Mozaffarnia S, Teimuri-Mofrad R, Rashidi MR. Design, synthesis and biological evaluation of 2,3-dihydro-5,6-dimethoxy-1H-inden-1-one and piperazinium salt hybrid derivatives as hAChE and hBuChE enzyme inhibitors. Eur J Med Chem. 2020;191:112140.","journal-title":"Eur J Med Chem"},{"key":"565_CR30","doi-asserted-by":"publisher","first-page":"103721","DOI":"10.1016\/j.bioorg.2020.103721","volume":"98","author":"A Xu","year":"2020","unstructured":"Xu A, He F, Zhang X, Li X, Ran Y, Wei C, et al. Tacrine-hydroxamate derivatives as multitarget-directed ligands for the treatment of Alzheimer\u2019s disease: design, synthesis, and biological evaluation. Bioorg Chem. 2020;98:103721.","journal-title":"Bioorg Chem"},{"key":"565_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/aps.2013.7","volume":"34","author":"JY Jia","year":"2013","unstructured":"Jia JY, Zhao QH, Liu Y, Gui YZ, Liu GY, Zhu DY, et al. Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease. Acta Pharmacol Sin. 2013;34:976\u201382.","journal-title":"Acta Pharmacol Sin"},{"key":"565_CR32","doi-asserted-by":"publisher","first-page":"103722","DOI":"10.1016\/j.bioorg.2020.103722","volume":"98","author":"E Plazas","year":"2020","unstructured":"Plazas E, Hagenow S, Avila Murillo M, Stark H, Cuca LE. Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and Abeta1-42 aggregation. Bioorg Chem. 2020;98:103722.","journal-title":"Bioorg Chem"},{"key":"565_CR33","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1021\/acsomega.9b03693","volume":"5","author":"N Augustin","year":"2020","unstructured":"Augustin N, Nuthakki VK, Abdullaha M, Hassan QP, Gandhi SG, Bharate SB. Discovery of helminthosporin, an anthraquinone isolated from Rumex abyssinicus Jacq as a dual cholinesterase inhibitor. ACS Omega. 2020;5:1616\u201324.","journal-title":"ACS Omega"},{"key":"565_CR34","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/bcp.12018","volume":"75","author":"DE Moss","year":"2013","unstructured":"Moss DE, Fariello RG, Sahlmann J, Sumaya I, Pericle F, Braglia E. A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer\u2019s disease. Br J Clin Pharmacol. 2013;75:1231\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"565_CR35","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/14756366.2020.1740694","volume":"35","author":"J Yang","year":"2020","unstructured":"Yang J, Yun Y, Miao Y, Sun J, Wang X. Synthesis and biological evaluation of 3-arylbenzofuranone derivatives as potential anti-Alzheimer\u2019s disease agents. J Enzym Inhib Med Chem. 2020;35:805\u201314.","journal-title":"J Enzym Inhib Med Chem"},{"key":"565_CR36","doi-asserted-by":"publisher","first-page":"115324","DOI":"10.1016\/j.bmc.2020.115324","volume":"28","author":"J Wu","year":"2020","unstructured":"Wu J, Pistolozzi M, Liu S, Tan W. Design, synthesis and biological evaluation of novel carbamates as potential inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2020;28:115324.","journal-title":"Bioorg Med Chem"},{"key":"565_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnins.2019.00043","volume":"13","author":"J Liu","year":"2019","unstructured":"Liu J, Chang L, Song Y, Li H, Wu Y. The role of NMDA receptors in Alzheimer\u2019s disease. Front Neurosci. 2019;13:43.","journal-title":"Front Neurosci"},{"key":"565_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/pharmaceutics12030284","volume":"12","author":"J Companys-Alemany","year":"2020","unstructured":"Companys-Alemany J, Turcu AL, Bellver-Sanchis A, Loza MI, Brea JM, Canudas AM, et al. A novel NMDA receptor antagonist protects against cognitive decline presented by senescent mice. Pharmaceutics. 2020;12:284.","journal-title":"Pharmaceutics"},{"key":"565_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejps.2019.02.018","volume":"131","author":"T Yang","year":"2019","unstructured":"Yang T, Shi Y, Lin C, Yan C, Zhang D, Lin J. Pharmacokinetics, bioavailability and tissue distribution study of JCC-02, a novel N-methyl-D-aspartate (NMDA) receptor inhibitor, in rats by LC-MS\/MS. Eur J Pharm Sci. 2019;131:146\u201352.","journal-title":"Eur J Pharm Sci"},{"key":"565_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fphar.2018.00073","volume":"9","author":"S Hu","year":"2018","unstructured":"Hu S, Hu H, Mak S, Cui G, Lee M, Shan L, et al. A novel tetramethylpyrazine derivative prophylactically protects against glutamate-induced excitotoxicity in primary neurons through the blockage of N-Methyl-D-aspartate receptor. Front Pharmacol. 2018;9:73.","journal-title":"Front Pharmacol"},{"key":"565_CR41","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.neuropharm.2018.03.007","volume":"135","author":"Y Yang","year":"2018","unstructured":"Yang Y, Ji WG, Zhu ZR, Wu YL, Zhang ZY, Qu SC. Rhynchophylline suppresses soluble Abeta1-42-induced impairment of spatial cognition function via inhibiting excessive activation of extrasynaptic NR2B-containing NMDA receptors. Neuropharmacology. 2018;135:100\u201312.","journal-title":"Neuropharmacology"},{"key":"565_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.neurobiolaging.2018.05.033","volume":"70","author":"NM Barcelos","year":"2018","unstructured":"Barcelos NM, Van Ness PH, Wagner AF, MacAvoy MG, Mecca AP, Anderson GM, et al. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. Neurobiol Aging. 2018;70:117\u201324.","journal-title":"Neurobiol Aging"},{"key":"565_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fphar.2015.00162","volume":"6","author":"O Stiedl","year":"2015","unstructured":"Stiedl O, Pappa E, Konradsson-Geuken A, Ogren SO. The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory. Front Pharmacol. 2015;6:162.","journal-title":"Front Pharmacol"},{"key":"565_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/alzrt169","volume":"5","author":"MJ Ramirez","year":"2013","unstructured":"Ramirez MJ. 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013;5:15.","journal-title":"Alzheimers Res Ther"},{"key":"565_CR45","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/13543784.2018.1483334","volume":"27","author":"R Khoury","year":"2018","unstructured":"Khoury R, Grysman N, Gold J, Patel K, Grossberg GT. The role of 5-HT6-receptor antagonists in Alzheimer's disease: an update. Expert Opin Investig Drugs. 2018;27:523\u201333.","journal-title":"Expert Opin Investig Drugs"},{"key":"565_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2017.20373","volume":"319","author":"A Atri","year":"2018","unstructured":"Atri A, Frolich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, et al. Effect of Idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA. 2018;319:130\u201342.","journal-title":"JAMA"},{"key":"565_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13195-018-0368-9","volume":"10","author":"T Fullerton","year":"2018","unstructured":"Fullerton T, Binneman B, David W, Delnomdedieu M, Kupiec J, Lockwood P, et al. A phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer\u2019s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil. Alzheimers Res Ther. 2018;10:38.","journal-title":"Alzheimers Res Ther"},{"key":"565_CR48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s13238-016-0338-6","volume":"8","author":"R Alkasir","year":"2017","unstructured":"Alkasir R, Li J, Li X, Jin M, Zhu B. Human gut microbiota: the links with dementia development. Protein Cell. 2017;8:90\u2013102.","journal-title":"Protein Cell"},{"key":"565_CR49","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/jnc.15031","volume":"155","author":"Z Li","year":"2020","unstructured":"Li Z, Zhu H, Guo Y, Du X, Qin C. Gut microbiota regulate cognitive deficits and amyloid deposition in a model of Alzheimer's disease. J Neurochem. 2020;155:448\u201361.","journal-title":"J Neurochem"},{"key":"565_CR50","doi-asserted-by":"crossref","unstructured":"Kim CS, Cha L, Sim M, Jung S, Chun WY, Baik HW, et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling elderly: a randomized, double-blind, placebo-controlled, multicenter trial. J Gerontol A Biol Sci Med Sci. 2020:glaa090.","DOI":"10.1093\/gerona\/glaa090"},{"key":"565_CR51","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40265-020-01268-1","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sodium oligomannate: first approval. Drugs. 2020;80:441\u20134.","journal-title":"Drugs"},{"key":"565_CR52","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","volume":"29","author":"X Wang","year":"2019","unstructured":"Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression. Cell Res. 2019;29:787\u2013803.","journal-title":"Cell Res"},{"key":"565_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41582-019-0307-9","volume":"16","author":"E Gyengesi","year":"2020","unstructured":"Gyengesi E, Munch G. In search of an anti-inflammatory drug for Alzheimer disease. Nat Rev Neurol. 2020;16:131\u20132.","journal-title":"Nat Rev Neurol"},{"key":"565_CR54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-141506","volume":"44","author":"J Wang","year":"2015","unstructured":"Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer\u2019s disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2015;44:385\u201396.","journal-title":"J Alzheimers Dis"},{"key":"565_CR55","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","volume":"77","author":"R Howard","year":"2019","unstructured":"Howard R, Zubko O, Bradley R, Harper E, Pank L, O\u2019Brien J, et al. Minocycline at 2 different dosages vs placebo for patients with mild alzheimer disease: a randomized clinical trial. JAMA Neurol. 2019;77:164\u201374.","journal-title":"JAMA Neurol"},{"key":"565_CR56","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tem.2010.05.005","volume":"21","author":"S Merlo","year":"2010","unstructured":"Merlo S, Spampinato S, Canonico PL, Copani A, Sortino MA. Alzheimer\u2019s disease: brain expression of a metabolic disorder? Trends Endocrinol Metab. 2010;21:537\u201344.","journal-title":"Trends Endocrinol Metab"},{"key":"565_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.tem.2016.12.001","volume":"28","author":"C Lane-Donovan","year":"2017","unstructured":"Lane-Donovan C, Herz JApoE. ApoE receptors, and the synapse in Alzheimer\u2019s disease. Trends Endocrinol Metab. 2017;28:273\u201384.","journal-title":"Trends Endocrinol Metab"},{"key":"565_CR58","doi-asserted-by":"crossref","unstructured":"Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012:CD005379.","DOI":"10.1002\/14651858.CD005379.pub3"},{"key":"565_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/JAD-180209","volume":"64","author":"JK Chhetri","year":"2018","unstructured":"Chhetri JK, de Souto Barreto P, Cantet C, Pothier K, Cesari M, Andrieu S, et al. Effects of a 3-year multi-domain intervention with or without Omega-3 supplementation on cognitive functions in older subjects with increased CAIDE dementia scores. J Alzheimers Dis. 2018;64:71\u20138.","journal-title":"J Alzheimers Dis"},{"key":"565_CR60","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1474-4422(17)30040-6","volume":"16","author":"S Andrieu","year":"2017","unstructured":"Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16:377\u201389.","journal-title":"Lancet Neurol"},{"key":"565_CR61","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.3390\/ijms20143531","volume":"20","author":"S Dhakal","year":"2019","unstructured":"Dhakal S, Subhan M, Fraser JM, Gardiner K, Macreadie I. Simvastatin efficiently reduces levels of Alzheimer\u2019s amyloid beta in yeast. Int J Mol Sci. 2019;20:3531.","journal-title":"Int J Mol Sci"},{"key":"565_CR62","doi-asserted-by":"publisher","first-page":"435","DOI":"10.21037\/atm.2018.06.43","volume":"6","author":"XC Zhu","year":"2018","unstructured":"Zhu XC, Dai WZ, Ma T. Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis. Ann Transl Med. 2018;6:435.","journal-title":"Ann Transl Med"},{"key":"565_CR63","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s10072-020-04243-6","volume":"41","author":"K Xuan","year":"2020","unstructured":"Xuan K, Zhao T, Qu G, Liu H, Chen X, Sun Y. The efficacy of statins in the treatment of Alzheimer\u2019s disease: a meta-analysis of randomized controlled trial. Neurol Sci. 2020;41:1391\u2013404.","journal-title":"Neurol Sci"},{"key":"565_CR64","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jagp.2019.11.003","volume":"28","author":"EC Kemp","year":"2020","unstructured":"Kemp EC, Ebner MK, Ramanan S, Godek TA, Pugh EA, Bartlett HH, et al. Statin use and risk of cognitive decline in the ADNI cohort. Am J Geriatr Psychiatry. 2020;28:507\u201317.","journal-title":"Am J Geriatr Psychiatry"},{"key":"565_CR65","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jgs.16342","volume":"68","author":"KAS Davis","year":"2020","unstructured":"Davis KAS, Bishara D, Perera G, Molokhia M, Rajendran L, Stewart RJ. Benefits and harms of statins in people with dementia: a systematic review and meta-analysis. J Am Geriatr Soc. 2020;68:650\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"565_CR66","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1212\/WNL.0000000000004818","volume":"90","author":"L Sinyavskaya","year":"2018","unstructured":"Sinyavskaya L, Gauthier S, Renoux C, Dell\u2019Aniello S, Suissa S, Brassard P. Comparative effect of statins on the risk of incident Alzheimer disease. Neurology. 2018;90:e179\u2013e87.","journal-title":"Neurology"},{"key":"565_CR67","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1084\/jem.20150956","volume":"212","author":"DC Rubinsztein","year":"2015","unstructured":"Rubinsztein DC, Bento CF, Deretic V. Therapeutic targeting of autophagy in neurodegenerative and infectious diseases. J Exp Med. 2015;212:979\u201390.","journal-title":"J Exp Med"},{"key":"565_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pneurobio.2013.03.001","volume":"105","author":"MJ Lee","year":"2013","unstructured":"Lee MJ, Lee JH, Rubinsztein DC. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol. 2013;105:49\u201359.","journal-title":"Prog Neurobiol"},{"key":"565_CR69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s13311-014-0320-z","volume":"12","author":"LG Friedman","year":"2015","unstructured":"Friedman LG, Qureshi YH, Yu WH. Promoting autophagic clearance: viable therapeutic targets in Alzheimer\u2019s disease. Neurotherapeutics. 2015;12:94\u2013108.","journal-title":"Neurotherapeutics"},{"key":"565_CR70","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jcis.2019.05.066","volume":"552","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhou H, Yin T, Gong Y, Yuan G, Chen L, et al. Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer\u2019s disease. J Colloid Interface Sci. 2019;552:388\u2013400.","journal-title":"J Colloid Interface Sci"},{"key":"565_CR71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.sleep.2004.12.005","volume":"6","author":"M Moran","year":"2005","unstructured":"Moran M, Lynch CA, Walsh C, Coen R, Coakley D, Lawlor BA. Sleep disturbance in mild to moderate Alzheimer\u2019s disease. Sleep Med. 2005;6:347\u201352.","journal-title":"Sleep Med"},{"key":"565_CR72","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3233\/JAD-150774","volume":"50","author":"H Qiu","year":"2016","unstructured":"Qiu H, Zhong R, Liu H, Zhang F, Li S, Le W. Chronic sleep deprivation exacerbates learning-memory disability and Alzheimer\u2019s disease-like pathologies in AbetaPP(swe)\/PS1(DeltaE9) mice. J Alzheimers Dis. 2016;50:669\u201385.","journal-title":"J Alzheimers Dis"},{"key":"565_CR73","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jalz.2018.12.004","volume":"15","author":"F Zhang","year":"2019","unstructured":"Zhang F, Zhong R, Li S, Fu Z, Wang R, Wang T, et al. Alteration in sleep architecture and electroencephalogram as an early sign of Alzheimer\u2019s disease preceding the disease pathology and cognitive decline. Alzheimers Dement. 2019;15:590\u20137.","journal-title":"Alzheimers Dement"},{"key":"565_CR74","doi-asserted-by":"publisher","first-page":"e12665","DOI":"10.1111\/jpi.12665","volume":"69","author":"D Chen","year":"2020","unstructured":"Chen D, Mei Y, Kim N, Lan G, Gan CL, Fan F, et al. Melatonin directly binds and inhibits death-associated protein kinase 1 function in Alzheimer\u2019s disease. J Pineal Res. 2020;69:e12665.","journal-title":"J Pineal Res."},{"key":"565_CR75","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/sleep\/26.7.893","volume":"26","author":"C Singer","year":"2003","unstructured":"Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer\u2019s disease. Sleep. 2003;26:893\u2013901.","journal-title":"Sleep"},{"key":"565_CR76","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/jamapsychiatry.2013.3320","volume":"71","author":"K Hatta","year":"2014","unstructured":"Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014;71:397\u2013403.","journal-title":"JAMA Psychiatry"},{"key":"565_CR77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neurobiolaging.2020.02.020","volume":"91","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yan XD, Wang C, He YX, Li YY, Zhang J, et al. Suvorexant ameliorates cognitive impairments and pathology in APP\/PS1 transgenic mice. Neurobiol Aging. 2020;91:66\u201375.","journal-title":"Neurobiol Aging"},{"key":"565_CR78","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","volume":"16","author":"WJ Herring","year":"2020","unstructured":"Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020;16:541\u201351.","journal-title":"Alzheimers Dement"},{"key":"565_CR79","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/cns.13095","volume":"25","author":"N Kandiah","year":"2019","unstructured":"Kandiah N, Ong PA, Yuda T, Ng LL, Mamun K, Merchant RA, et al. Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: expert consensus on the use of Ginkgo biloba extract, EGb 761((R)). CNS Neurosci Ther. 2019;25:288\u201398.","journal-title":"CNS Neurosci Ther"},{"key":"565_CR80","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1021\/acs.jafc.8b04514","volume":"67","author":"LC Kuo","year":"2019","unstructured":"Kuo LC, Song YQ, Yao CA, Cheng IH, Chien CT, Lee GC, et al. Ginkgolide A prevents the amyloid-beta-induced depolarization of cortical neurons. J Agric Food Chem. 2019;67:81\u20139.","journal-title":"J Agric Food Chem"},{"key":"565_CR81","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/ADR-190135","volume":"3","author":"TK Das","year":"2019","unstructured":"Das TK, Jana P, Chakrabarti SK, Abdul Hamid MRW. Curcumin downregulates GSK3 and Cdk5 in scopolamine-induced Alzheimer\u2019s disease rats abrogating Abeta40\/42 and tau hyperphosphorylation. J Alzheimers Dis Rep. 2019;3:257\u201367.","journal-title":"J Alzheimers Dis Rep"},{"key":"565_CR82","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/nu12041032","volume":"12","author":"RN Thota","year":"2020","unstructured":"Thota RN, Rosato JI, Dias CB, Burrows TL, Martins RN, Garg ML. Dietary supplementation with curcumin reduce circulating levels of glycogen synthase kinase-3beta and islet amyloid polypeptide in adults with high risk of type 2 diabetes and Alzheimer\u2019s disease. Nutrients. 2020;12:1032.","journal-title":"Nutrients"},{"key":"565_CR83","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3233\/JAD-180184","volume":"65","author":"JE de la Rubia Orti","year":"2018","unstructured":"de la Rubia Orti JE, Garcia-Pardo MP, Drehmer E, Sancho Cantus D, Julian Rochina M, Aguilar MA, et al. Improvement of main cognitive functions in patients with Alzheimer\u2019s disease after treatment with coconut oil enriched Mediterranean diet: a pilot study. J Alzheimers Dis. 2018;65:577\u201387.","journal-title":"J Alzheimers Dis"},{"key":"565_CR84","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10571-015-0233-3","volume":"36","author":"Z Cai","year":"2016","unstructured":"Cai Z, Liu N, Wang C, Qin B, Zhou Y, Xiao M, et al. Role of RAGE in Alzheimer\u2019s disease. Cell Mol Neurobiol. 2016;36:483\u201395.","journal-title":"Cell Mol Neurobiol"},{"key":"565_CR85","first-page":"149","volume":"5","author":"AH Burstein","year":"2018","unstructured":"Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L. Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2018;5:149\u201354.","journal-title":"J Prev Alzheimers Dis"},{"key":"565_CR86","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jphs.2014.11.011","volume":"127","author":"K Ruscher","year":"2015","unstructured":"Ruscher K, Wieloch T. The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration. J Pharmacol Sci. 2015;127:30\u20135.","journal-title":"J Pharmacol Sci"},{"key":"565_CR87","doi-asserted-by":"crossref","first-page":"e12013","DOI":"10.1002\/trc2.12013","volume":"6","author":"H Hampel","year":"2020","unstructured":"Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer\u2019s disease therapy: analysis of the blarcamesine (ANAVEX2-73) phase 2a clinical study. Alzheimers Dement. 2020;6:e12013.","journal-title":"Alzheimers Dement"},{"key":"565_CR88","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/13543784.2017.1267726","volume":"26","author":"RP Garay","year":"2017","unstructured":"Garay RP, Grossberg GT. AVP-786 for the treatment of agitation in dementia of the Alzheimer\u2019s type. Expert Opin Investig Drugs. 2017;26:121\u201332.","journal-title":"Expert Opin Investig Drugs"},{"key":"565_CR89","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.omtn.2020.01.027","volume":"19","author":"SG Poplawski","year":"2020","unstructured":"Poplawski SG, Garbett KA, McMahan RL, Kordasiewicz HB, Zhao H, Kennedy AJ, et al. An antisense oligonucleotide leads to suppressed transcription of Hdac2 and long-term memory enhancement. Mol Ther Nucleic Acids. 2020;19:1399\u2013412.","journal-title":"Mol Ther Nucleic Acids"},{"key":"565_CR90","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/iub.2330","volume":"72","author":"L Lv","year":"2020","unstructured":"Lv L, Yang F, Li H, Yuan J. Brain-targeted co-delivery of beta-amyloid converting enzyme 1 shRNA and epigallocatechin-3-gallate by multifunctional nanocarriers for Alzheimer\u2019s disease treatment. IUBMB Life. 2020;72:1819\u201329.","journal-title":"IUBMB Life"},{"key":"565_CR91","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fphar.2019.00665","volume":"10","author":"F Angelucci","year":"2019","unstructured":"Angelucci F, Cechova K, Valis M, Kuca K, Zhang B, Hort J. MicroRNAs in Alzheimer\u2019s disease: diagnostic markers or therapeutic agents? Front Pharmacol. 2019;10:665.","journal-title":"Front Pharmacol"},{"key":"565_CR92","doi-asserted-by":"crossref","unstructured":"Chopra N, Wang R, Maloney B, Nho K, Beck JS, Pourshafie N, et al. MicroRNA-298 reduces levels of human amyloid-beta precursor protein (APP), beta-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. Mol Psychiatry. 2020.","DOI":"10.1038\/s41380-019-0610-2"},{"key":"565_CR93","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.omtn.2020.01.010","volume":"19","author":"AT Barros-Viegas","year":"2020","unstructured":"Barros-Viegas AT, Carmona V, Ferreiro E, Guedes J, Cardoso AM, Cunha P, et al. miRNA-31 improves cognition and abolishes Amyloid-beta pathology by targeting APP and BACE1 in an animal model of Alzheimer\u2019s disease. Mol Ther Nucleic Acids. 2020;19:1219\u201336.","journal-title":"Mol Ther Nucleic Acids"},{"key":"565_CR94","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.omtn.2019.10.002","volume":"18","author":"H Mai","year":"2019","unstructured":"Mai H, Fan W, Wang Y, Cai Y, Li X, Chen F, et al. Intranasal administration of miR-146a Agomir rescued the pathological process and cognitive impairment in an AD mouse model. Mol Ther Nucleic Acids. 2019;18:681\u201395.","journal-title":"Mol Ther Nucleic Acids"},{"key":"565_CR95","doi-asserted-by":"publisher","first-page":"116793","DOI":"10.1016\/j.jns.2020.116793","volume":"413","author":"P Li","year":"2020","unstructured":"Li P, Xu Y, Wang B, Huang J, Li Q. miR-34a-5p and miR-125b-5p attenuate Abeta-induced neurotoxicity through targeting BACE1. J Neurol Sci. 2020;413:116793.","journal-title":"J Neurol Sci"},{"key":"565_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-200219","volume":"77","author":"J Kim","year":"2020","unstructured":"Kim J, Lee Y, Lee S, Kim K, Song M, Lee J.Mesenchymal stem cell therapy and Alzheimer\u2019s disease: current status and future perspectives. J Alzheimers Dis. 2020;77:1\u201314.","journal-title":"J Alzheimers Dis"},{"key":"565_CR97","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40035-020-00199-x","volume":"9","author":"C Qin","year":"2020","unstructured":"Qin C, Lu Y, Wang K, Bai L, Shi G, Huang Y, et al. Transplantation of bone marrow mesenchymal stem cells improves cognitive deficits and alleviates neuropathology in animal models of Alzheimer\u2019s disease: a meta-analytic review on potential mechanisms. Transl Neurodegener. 2020;9:20.","journal-title":"Transl Neurodegener"},{"key":"565_CR98","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4252\/wjsc.v12.i5.323","volume":"12","author":"J Wang","year":"2020","unstructured":"Wang J, Hu WW, Jiang Z, Feng MJ. Advances in treatment of neurodegenerative diseases: perspectives for combination of stem cells with neurotrophic factors. World J Stem Cells. 2020;12:323\u201338.","journal-title":"World J Stem Cells"},{"key":"565_CR99","doi-asserted-by":"crossref","unstructured":"Santamaria G, Brandi E, Vitola P, Grandi F, Ferrara G, Pischiutta F, et al. Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer\u2019s mice. Cell Death Differ. 2020.","DOI":"10.1038\/s41418-020-0592-2"},{"key":"565_CR100","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.trci.2015.06.007","volume":"1","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Seo SW, Chang JW, Lee JI, Kim CH, Chin J, et al. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: a phase 1 clinical trial. Alzheimers Dement. 2015;1:95\u2013102.","journal-title":"Alzheimers Dement"},{"key":"565_CR101","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/alzrt189","volume":"5","author":"A Bahar-Fuchs","year":"2013","unstructured":"Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer\u2019s or vascular type: a review. Alzheimers Res Ther. 2013;5:35.","journal-title":"Alzheimers Res Ther"},{"key":"565_CR102","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1021\/acschemneuro.8b00442","volume":"10","author":"F Zhang","year":"2019","unstructured":"Zhang F, Niu L, Li S, Le W.Pathological impacts of chronic hypoxia on Alzheimer\u2019s disease. ACS Chem Neurosci. 2019;10:902","journal-title":"ACS Chem Neurosci"},{"key":"565_CR103","doi-asserted-by":"crossref","first-page":"e12030","DOI":"10.1002\/trc2.12030","volume":"6","author":"J Chen","year":"2020","unstructured":"Chen J, Zhang F, Zhao L, Cheng C, Zhong R, Dong C, et al. Hyperbaric oxygen ameliorates cognitive impairment in patients with Alzheimer\u2019s disease and amnestic mild cognitive impairment. Alzheimers Dement. 2020;6:e12030.","journal-title":"Alzheimers Dement"},{"key":"565_CR104","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.clinph.2014.04.010","volume":"125","author":"M Cantone","year":"2014","unstructured":"Cantone M, Di Pino G, Capone F, Piombo M, Chiarello D, Cheeran B, et al. The contribution of transcranial magnetic stimulation in the diagnosis and in the management of dementia. Clin Neurophysiol. 2014;125:1509\u201332.","journal-title":"Clin Neurophysiol"},{"key":"565_CR105","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.brs.2012.03.004","volume":"5","author":"R Manenti","year":"2012","unstructured":"Manenti R, Cotelli M, Robertson IH, Miniussi C. Transcranial brain stimulation studies of episodic memory in young adults, elderly adults and individuals with memory dysfunction: a review. Brain Stimul. 2012;5:103\u20139.","journal-title":"Brain Stimul"},{"key":"565_CR106","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-016-0180-3","volume":"8","author":"M Bystad","year":"2016","unstructured":"Bystad M, Gronli O, Rasmussen ID, Gundersen N, Nordvang L, Wang-Iversen H, et al. Transcranial direct current stimulation as a memory enhancer in patients with Alzheimer\u2019s disease: a randomized, placebo-controlled trial. Alzheimers Res Ther. 2016;8:13.","journal-title":"Alzheimers Res Ther"},{"key":"565_CR107","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ana.21295","volume":"63","author":"C Hamani","year":"2008","unstructured":"Hamani C, McAndrews MP, Cohn M, Oh M, Zumsteg D, Shapiro CM, et al. Memory enhancement induced by hypothalamic\/fornix deep brain stimulation. Ann Neurol. 2008;63:119\u201323.","journal-title":"Ann Neurol"},{"key":"565_CR108","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12017-009-8109-7","volume":"12","author":"RA Sperling","year":"2010","unstructured":"Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, et al. Functional alterations in memory networks in early Alzheimer\u2019s disease. Neuromolecular Med. 2010;12:27\u201343.","journal-title":"Neuromolecular Med"},{"key":"565_CR109","doi-asserted-by":"crossref","unstructured":"Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012:CD005562.","DOI":"10.1002\/14651858.CD005562.pub2"},{"key":"565_CR110","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1001\/jama.299.22.2642","volume":"299","author":"RF Riemersma-van der Lek","year":"2008","unstructured":"Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299:2642\u201355.","journal-title":"JAMA"},{"key":"565_CR111","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/jgs.14059","volume":"64","author":"H Ohman","year":"2016","unstructured":"Ohman H, Savikko N, Strandberg TE, Kautiainen H, Raivio MM, Laakkonen ML, et al. Effects of exercise on cognition: the Finnish Alzheimer disease exercise trial: a randomized, controlled trial. J Am Geriatr Soc. 2016;64:731\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"565_CR112","doi-asserted-by":"publisher","first-page":"101108","DOI":"10.1016\/j.arr.2020.101108","volume":"62","author":"PL Valenzuela","year":"2020","unstructured":"Valenzuela PL, Castillo-Garcia A, Morales JS, la Villa P, Hampel H, Emanuele E, et al. Exercise benefits on Alzheimer\u2019s disease: state-of-the-science. Ageing Res Rev. 2020;62:101108.","journal-title":"Ageing Res Rev"},{"key":"565_CR113","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fnagi.2020.00098","volume":"12","author":"YY Wang","year":"2020","unstructured":"Wang YY, Yu SF, Xue HY, Li Y, Zhao C, Jin YH. Effectiveness and safety of acupuncture for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2020;12:98.","journal-title":"Front Aging Neurosci"},{"key":"565_CR114","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/nyas.12621","volume":"1337","author":"S Samson","year":"2015","unstructured":"Samson S, Clement S, Narme P, Schiaratura L, Ehrle N. Efficacy of musical interventions in dementia: methodological requirements of nonpharmacological trials. Ann N Y Acad Sci. 2015;1337:249\u201355.","journal-title":"Ann N Y Acad Sci"},{"key":"565_CR115","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1080\/07391102.2019.1633408","volume":"38","author":"S Agatonovic-Kustrin","year":"2020","unstructured":"Agatonovic-Kustrin S, Chan CKY, Gegechkori V, Morton DW. Models for skin and brain penetration of major components from essential oils used in aromatherapy for dementia patients. J Biomol Struct Dyn. 2020;38:2402\u201311.","journal-title":"J Biomol Struct Dyn"},{"key":"565_CR116","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3171\/2016.1.PEDS15534","volume":"18","author":"D Revesz","year":"2016","unstructured":"Revesz D, Rydenhag B, Ben-Menachem E. Complications and safety of vagus nerve stimulation: 25 years of experience at a single center. J Neurosurg Pediatr. 2016;18:97\u2013104.","journal-title":"J Neurosurg Pediatr"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00565-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T08:20:36Z","timestamp":1697271636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00565-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":116,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-00565-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,2]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}